{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:38:38Z","timestamp":1745469518309,"version":"3.40.4"},"reference-count":20,"publisher":"S. Karger AG","issue":"5-6","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2010]]},"abstract":"<i>Purpose:<\/i> To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer. <i>Patients and Methods:<\/i> Patients with histologically confirmed nonresectable biliary adenocarcinoma were treated with oxaliplatin (85 mg\/m<sup>2<\/sup>) and irinotecan (200 mg\/m<sup>2<\/sup>) every 3 weeks.<i>Results:<\/i> Twenty-eight patients were enrolled between May 2005 and March 2009. The overall objective response rate was 17.9% with an additional 21.4% of patients with stable disease (disease control rate 39.3%). The median overall survival time was 9.2 months (95% CI 5.8\u201312.5) and the median progression-free survival time 2.7 months (95% CI 2.2\u20133.2). Grades 3 and 4 neutropenia occurred in 1 (3.6%) and 4 (14.3%) patients, respectively, and febrile neutropenia in 3 (10.7%). Grade 3\u20134 diarrhea was observed in 2 (7.1%) patients and grade 3 asthenia in 1 (6%). There were no treatment-related deaths. <i>Conclusion:<\/i> The combination of oxaliplatin and irinotecan has a modest antitumor activity with manageable toxicity as first-line treatment in metastatic cancer of the biliary tract and therefore it cannot be recommended as front-line treatment for unresectable biliary tract cancer.<\/jats:p>","DOI":"10.1159\/000320462","type":"journal-article","created":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T08:50:25Z","timestamp":1282812625000},"page":"356-360","source":"Crossref","is-referenced-by-count":13,"title":["A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable\/Metastatic Cancer of the Biliary Tract"],"prefix":"10.1159","volume":"78","author":[{"given":"Niki","family":"Karachaliou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kentepozidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Ziras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Vardakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Kalykaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Milaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Androulakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2010,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00280-008-0883-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6605211"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00280-009-1018-5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00534-007-1280-z"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1011135014895"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.05.029"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6602576"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdh351"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.51.008"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2008.16.5704"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00280-009-1069-7"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097%2F01.coc.0000258124.72884.7a"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1385%2FIJGC%3A32%3A2-3%3A107"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097%2FCAD.0b013e3283287ca0"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6604178"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdh312"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2F0197-2456%2889%2990015-9"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2307%2F2281868"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159%2F000096249"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159%2F000159624"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/320462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/320462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:51:47Z","timestamp":1745437907000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000320462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":20,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2010,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000320462","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2010]]}}}